

Jonathan P Bestwick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3874531/publications.pdf>

Version: 2024-02-01

101
papers

5,135
citations

159358

30
h-index

91712

69
g-index

105
all docs

105
docs citations

105
times ranked

8137
citing authors

#	ARTICLE	IF	CITATIONS
1	A non-injected opioid analgesia protocol for acute pain crisis in adolescents and adults with sickle cell disease. <i>British Journal of Pain</i> , 2022, 16, 179-190.	0.7	1
2	<scp>COVID</scp>â€19 Vaccine Response in People with Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 89-100.	2.8	119
3	Developing and assessing a new web-based tapping test for measuring distal movement in Parkinsonâ€™s disease: a Distal Finger Tapping test. <i>Scientific Reports</i> , 2022, 12, 386.	1.6	22
4	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. <i>Lancet Regional Health - Europe</i> , The, 2022, 15, 100321.	3.0	13
5	The potential utility of smell testing to screen for neurodegenerative disorders. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 139-148.	1.5	1
6	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. <i>JAMA Neurology</i> , 2022, 79, 359.	4.5	25
7	The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 2754-2760.	1.7	5
8	026â€... Gene-environment interactions in multiple sclerosis: a UK Biobank study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A21.3-A22.	0.9	0
9	Ethnic and socioeconomic determinants of dementia risk: a nested case-control study in East London. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A8.2-A8.	0.9	0
10	Parkinsonâ€™s disease determinants, prediction and gene-environment interactions: a UK Biobank study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A7.3-A8.	0.9	0
11	Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e711-e720.	1.8	17
12	Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. <i>Movement Disorders</i> , 2021, 36, 1420-1429.	2.2	108
13	Improving estimation of Parkinsonâ€™s disease riskâ€”the enhanced PREDICT-PD algorithm. <i>Npj Parkinson's Disease</i> , 2021, 7, 33.	2.5	13
14	Gene-Environment Interactions in Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	32
15	Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinsonâ€™s Disease and Idiopathic Anosmia. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1901-1915.	1.5	6
16	Optimising classification of Parkinsonâ€™s disease based on motor, olfactory, neuropsychiatric and sleep features. <i>Npj Parkinson's Disease</i> , 2021, 7, 87.	2.5	4
17	Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies. <i>Atherosclerosis</i> , 2020, 293, 57-61.	0.4	32
18	Parkinsonâ€™s disease determinants, prediction and geneâ€environment interactions in the UK Biobank. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1046-1054.	0.9	59

#	ARTICLE	IF	CITATIONS
19	Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 278-291.	5.5	60
20	Should fractional flow reserve follow angiographic visual inspection to guide preventive percutaneous coronary intervention in ST-elevation myocardial infarction?. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 186-192.	1.8	15
21	English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 168-181.	1.9	8
22	Cost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13. <i>PLoS ONE</i> , 2019, 14, e0220053.	1.1	1
23	Evolution and clustering of prodromal parkinsonian features in <i>GBA1</i> carriers. <i>Movement Disorders</i> , 2019, 34, 1365-1373.	2.2	33
24	Randomized Crossover Trial of Phosphate-binding Medication on Serum Phosphate Levels in Patients With Aortic Stenosis. <i>Clinical Therapeutics</i> , 2019, 41, 2066-2072.e2.	1.1	3
25	A simple method to allow for guanine-cytosine amplification error in prenatal DNA screening for trisomy 18. <i>Clinica Chimica Acta</i> , 2019, 496, 13-17.	0.5	0
26	Ethnic access to child-parent screening for familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1341-1342.	0.8	0
27	A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 523-538.	1.8	36
28	Association between serum calcium, serum phosphate and aortic stenosis with implications for prevention. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 551-556.	0.8	12
29	Dopamine reuptake transporter single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 478-482.	2.2	25
30	Watchful Waiting in Aortic Stenosis: The Problem of Acute Decompensation. <i>American Journal of Medicine</i> , 2018, 131, 173-177.	0.6	20
31	Prenatal reflex DNA screening for trisomies 21, 18, and 13. <i>Genetics in Medicine</i> , 2018, 20, 825-830.	1.1	24
32	Evaluation of stability of directly standardized rates for sparse data using simulation methods. <i>Population Health Metrics</i> , 2018, 16, 19.	1.3	10
33	Scanning electron microscopy for blood micro-crystals in aortic stenosis patients. <i>PLoS ONE</i> , 2018, 13, e0202282.	1.1	0
34	Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies. <i>Prenatal Diagnosis</i> , 2018, 38, 1079-1085.	1.1	4
35	Specifying a Gold Standard for the Validation of Fetal Fraction Estimation in Prenatal Screening. <i>Clinical Chemistry</i> , 2018, 64, 1394-1399.	1.5	7
36	Serum marker truncation limits in first trimester antenatal screening for trisomy 18. <i>Journal of Medical Screening</i> , 2018, 25, 169-173.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Response to Walker. <i>Genetics in Medicine</i> , 2018, 20, 1295-1295.	1.1	4
38	Childâ€‘Parent Familial Hypercholesterolemia Screening in Primary Care. <i>New England Journal of Medicine</i> , 2017, 376, 498-500.	13.9	11
39	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 219-226.	2.2	59
40	Subtle motor disturbances in PREDICT-PD participants. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 212-217.	0.9	19
41	Prenatal maternal plasma DNA screening for cystic fibrosis: A computer modelling study of screening performance. <i>F1000Research</i> , 2017, 6, 1896.	0.8	2
42	Preventive percutaneous coronary intervention and aspiration thrombectomyâ€‘updates in the management of ST-elevation myocardial infarction. <i>Journal of Thoracic Disease</i> , 2016, 8, 1908-1912.	0.6	4
43	Insulin dependent diabetes mellitus (IDDM) and first trimester markers in prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2016, 36, 192-193.	1.1	4
44	The Reply. <i>American Journal of Medicine</i> , 2016, 129, e33.	0.6	0
45	Childâ€‘Parent Familial Hypercholesterolemia Screening in Primary Care. <i>New England Journal of Medicine</i> , 2016, 375, 1628-1637.	13.9	250
46	Prenatal reflex DNA screening for Down syndrome: enhancing the screening performance of the initial first trimester test. <i>Prenatal Diagnosis</i> , 2016, 36, 328-331.	1.1	4
47	Antenatal reflex DNA screening for Downâ€™s syndrome using total instead of free B-hCG in the Combined test. <i>Journal of Medical Screening</i> , 2016, 23, 50-51.	1.1	0
48	Antenatal reflex DNA screening for trisomy 18 and trisomy 13 in addition to Downâ€™s syndrome. <i>Journal of Medical Screening</i> , 2016, 23, 171-174.	1.1	2
49	Sequential integrated antenatal screening for Downâ€™s syndrome, trisomy 18 and trisomy 13. <i>Journal of Medical Screening</i> , 2016, 23, 116-123.	1.1	0
50	Constipation preceding Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 710-716.	0.9	152
51	Webâ€‘based assessment of Parkinson's prodromal markers identifies GBA variants. <i>Movement Disorders</i> , 2015, 30, 1002-1003.	2.2	6
52	Reflex antenatal DNA screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2015, 35, 1154-1154.	1.1	9
53	Systematic review and metaâ€‘analysis of salivary protein concentration in <sc>P</sc>arkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1971-1972.	2.2	2
54	Antenatal screening for Downâ€™s syndrome, trisomy 18, and trisomy 13: Reporting a single screening result for all three. <i>Journal of Medical Screening</i> , 2015, 22, 100-105.	1.1	3

#	ARTICLE	IF	CITATIONS
55	Performance of antenatal reflex DNA screening for Downâ€™s syndrome. <i>Journal of Medical Screening</i> , 2015, 22, 168-174.	1.1	12
56	Retrospective observational comparative study of Hemilaminectomy versus Laminectomy for intraspinal tumour resection; Shorter Stays, Lower Analgesic Usage and Less Kyphotic Deformity. <i>British Journal of Neurosurgery</i> , 2015, 29, 390-395.	0.4	14
57	Prevalence of DNA-confirmed familial hypercholesterolaemia in young patients with myocardial infarction. <i>European Journal of Internal Medicine</i> , 2015, 26, 127-130.	1.0	39
58	One-way Versus Two-way Text Messaging on Improving Medication Adherence: Meta-analysis of Randomized Trials. <i>American Journal of Medicine</i> , 2015, 128, 1139.e1-1139.e5.	0.6	88
59	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 273-279.	0.9	144
60	Preventive Percutaneous Coronary Intervention in ST-elevation Myocardial Infarction â€“ The Primacy of Randomised Trials. <i>Interventional Cardiology Review</i> , 2015, 10, 32.	0.7	2
61	Prevention of Neural Tube Defects: A Cross-Sectional Study of the Uptake of Folic Acid Supplementation in Nearly Half a Million Women. <i>PLoS ONE</i> , 2014, 9, e89354.	1.1	82
62	Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function. <i>PLoS ONE</i> , 2014, 9, e96260.	1.1	52
63	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 31-37.	0.9	90
64	Bone health in Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1159-1166.	0.9	114
65	Effect of smoking status on inhibin-A in second-trimester prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2014, 34, 406-407.	1.1	2
66	The estimation of median nuchal translucency values between 10 and 14 weeks of pregnancy. <i>Journal of Medical Screening</i> , 2014, 21, 110-112.	1.1	4
67	The role of venous blood gas in the Emergency Department. <i>European Journal of Emergency Medicine</i> , 2014, 21, 81-88.	0.5	106
68	The area under the ROC curve: Is it a valid measure of screening performance?. <i>Journal of Medical Screening</i> , 2014, 21, 220-220.	1.1	4
69	Genetic comorbidities in Parkinson's disease. <i>Human Molecular Genetics</i> , 2014, 23, 831-841.	1.4	57
70	Thyroid stimulating hormone and free thyroxine in pregnancy: Expressing concentrations as multiples of the median (MoMs). <i>Clinica Chimica Acta</i> , 2014, 430, 33-37.	0.5	55
71	Maternal Perchlorate Levels in Women With Borderline Thyroid Function During Pregnancy and the Cognitive Development of Their Offspring: Data From the Controlled Antenatal Thyroid Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4291-4298.	1.8	85
72	Randomised Trial of Text Messaging on Adherence to Cardiovascular Preventive Treatment (INTERACT) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.1	84

#	ARTICLE	IF	CITATIONS
73	A comparative study of CSF neurofilament light and heavy chain protein in MS. Multiple Sclerosis Journal, 2013, 19, 1597-1603.	1.4	122
74	Allowing for ethnic group in antenatal screening for Down's syndrome. Journal of Medical Screening, 2013, 20, 52-54.	1.1	4
75	Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers. Journal of Medical Screening, 2013, 20, 57-65.	1.1	19
76	Incorporating DNA Sequencing into Current Prenatal Screening Practice for Down's Syndrome. PLoS ONE, 2013, 8, e58732.	1.1	27
77	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	1.1	375
78	Antenatal Thyroid Screening and Childhood Cognitive Function. New England Journal of Medicine, 2012, 366, 493-501.	13.9	553
79	The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia. Journal of Medical Screening, 2012, 19, 51-54.	1.1	13
80	Reply. European Thyroid Journal, 2012, 1, 134-134.	1.2	0
81	Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	2.8	607
82	Screening for pre-eclampsia using serum placental growth factor and endoglin with Down's syndrome Quadruple test markers. Journal of Medical Screening, 2012, 19, 60-67.	1.1	6
83	Adding ductus venosus blood flow as a categorical variable to the Combined and Integrated tests in Down's syndrome screening. Journal of Medical Screening, 2012, 19, 49-50.	1.1	5
84	Homocysteine as a Cause of Ischemic Heart Disease: The Door Remains Open. Clinical Chemistry, 2012, 58, 1488-1490.	1.5	10
85	Body weight reduction to avoid the excess risk of type 2 diabetes. British Journal of General Practice, 2012, 62, e411-e414.	0.7	10
86	Unconjugated estriol values between 14 and 22 weeks of gestation in relation to prenatal screening for Down syndrome. Prenatal Diagnosis, 2012, 32, 299-301.	1.1	6
87	Effect of interrupting prenatal Down syndrome screening due to a large nuchal translucency. Prenatal Diagnosis, 2012, 32, 655-661.	1.1	1
88	Child-Parent Screening for Familial Hypercholesterolemia. Journal of Pediatrics, 2011, 159, 865-867.	0.9	39
89	Distribution of Nuchal Translucency in Antenatal Screening for Down's Syndrome. Journal of Medical Screening, 2010, 17, 8-12.	1.1	16
90	Evaluation of a Proposed Mixture Model to Specify the Distributions of Nuchal Translucency Measurements in Antenatal Screening for Down's Syndrome. Journal of Medical Screening, 2010, 17, 13-18.	1.1	1

#	ARTICLE	IF	CITATIONS
91	Perchlorate and Thiocyanate Exposure and Thyroid Function in First-Trimester Pregnant Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3207-3215.	1.8	106
92	Combining Carotid Intima-media Thickness with Carotid Plaque on Screening for Coronary Heart Disease. <i>Journal of Medical Screening</i> , 2009, 16, 155-159.	1.1	5
93	The value of C-reactive protein in screening for future coronary heart disease events. <i>Journal of Medical Screening</i> , 2009, 16, 212-214.	1.1	6
94	Carotid Ultrasound Screening for Coronary Heart Disease: Results Based on a meta-analysis of 18 Studies and 44,861 Subjects. <i>Journal of Medical Screening</i> , 2009, 16, 147-154.	1.1	16
95	Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. <i>American Journal of Medicine</i> , 2009, 122, 290-300.	0.6	747
96	A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a β -blocker on blood pressure reduction. <i>Clinical Therapeutics</i> , 2008, 30, 2030-2039.	1.1	4
97	First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free β human chorionic gonadotrophin, pregnancy-associated plasma protein-A and nuchal translucency. <i>Journal of Medical Screening</i> , 2008, 15, 204-206.	1.1	19
98	Patients' attitudes towards the presence of medical students during consultations. <i>Medical Teacher</i> , 2006, 28, e198-e203.	1.0	52
99	Cross-trimester marker ratios in prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2006, 26, 514-523.	1.1	20
100	Sequential and contingent prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2006, 26, 769-777.	1.1	59
101	Cross trimester marker ratios: parameter estimates valid with no inconsistency. <i>Prenatal Diagnosis</i> , 2006, 26, 994-994.	1.1	1